Recruiting

Testing immune cells redirected to fight advanced melanoma and sarcoma

Plain-English translation of NCT06889766 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new immunotherapy called LauT-1, which is made from your own immune cells that have been genetically modified in the laboratory to recognize and attack cancer cells. The modified cells are designed to find and destroy melanoma or sarcoma tumors that express a specific protein called NY-ESO-1. You would receive chemotherapy and low-dose radiation before the treatment to help your body accept and expand these new cells.

Advanced melanoma and sarcoma are aggressive cancers that often stop responding to current standard treatments. This trial exists because researchers believe that training your own immune system to recognize these specific cancers may offer a new option when other treatments have failed.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced melanoma (without spread to the brain) or sarcoma that has stopped responding to or progressed on at least one prior standard treatment
your tumor cells express the NY-ESO-1 protein (confirmed by a biopsy showing this marker in at least 50% of your cancer cells)
you have specific HLA genetic markers (HLA-A*0201 or HLA-A*0205) that are necessary for this treatment to work
you are at least 18 years old and in reasonably good health with an expected life expectancy of more than 12 weeks
you are able to undergo apheresis (a procedure to collect your white blood cells) and have at least one tumor lesion that can be safely biopsied

You likely don't qualify if…

you have untreated or symptomatic brain metastases (cancer spread to the brain)
you have a second active cancer diagnosis
you have had a previous stem cell transplant or organ transplant
you are currently taking regular immunosuppressive medications like steroids
you have a history of serious lung disease, recent heart attack, or unstable heart condition

What participation looks like

First, your tumor will be tested to confirm it has the NY-ESO-1 protein and that you have the right HLA markers. If you qualify, you'll undergo apheresis to collect your white blood cells, which are then sent to the laboratory for genetic modification. While your cells are being prepared, you'll receive chemotherapy and low-dose radiation to prepare your body. Once your modified cells are ready, they will be infused back into you. You'll then be closely monitored with blood tests, imaging, and tumor biopsies to evaluate how well the treatment works and watch for any side effects.

AI-generated summary from trial data · Jun 9, 2026 · Not medical advice

Trial locations(2 sites)

Switzerland

Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Canton of Vaud

Centre Hospitalier Universitaire Vaudois, Lausanne, Canton of Vaud